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Singapore is investing heavily in stem cell research. This investment is part of an ambitious 
biomedical science initiative designed to enhance its thriving economy.Science is a global enterprise. Never-
theless, postal codes tend to influence 
views about where it is possible to do 
good science. For example, following the 
announcement of the birth of Dolly the 
Sheep in Roslin, Scotland (Wilmut et al., 
1997), many quipped “…but where is this 
place, Roslin?” In fact, Roslin was already 
notable for being a purported burial site of 
the Holy Grail (a fable embellished in the 
recent bestseller The Da Vinci Code). Sin-
gapore may lay no historical claim to the 
Grail but, not unlike Roslin, has emerged 
quite suddenly into the global biomedi-
cal science arena, jostling for attention in 
the face of considerable skepticism. But 
how can tiny Singapore hope to compete 
against larger nations with long-standing 
research programs? One strategy has 
been for Singapore to focus its efforts 
on select R&D targets, and one of these 
research areas is stem cells.
Singapore is a small densely popu-
lated city-state, situated one degree 
north of the Equator and dwarfed by 
its nearest neighbors, Malaysia and 
Indonesia. In land mass, it ranks 180th 
of 215 countries, but in terms of Pur-
chasing Power Parity per capita, it was 
ranked 21st among 180 member coun-
tries by the International Monetary Fund 
in 2007. To date, Singapore’s prosper-
ity has been secured by astute financial 
management and investment in a stra-
tegically designed portfolio including 
chemicals, electronic manufacturing, 
port activities, and financial services. 
The 12-fold surge in per capita wealth 
between 1960 (Singapore won inde-
pendence first from the UK and then 
from Malaysia in 1965) and 2000 (Hoon 
and Ho, 2006) signaled Singapore’s 
movement from third world to first and 
was based primarily on manufacturing. 
But regional competition from cheaper 
labor locations has led Singapore to embrace knowledge-based industries, 
specifically the biomedical sciences, 
over the past 8 years. In 2000, the 
Singaporean Government set up the 
Agency for Science Technology and 
Research (A*STAR), and between 2001 
and 2010, it will have invested more 
than US $4 billion in infrastructural and 
operational support for existing and 
new thematic research facilities and 
institutes in the biomedical sciences. 
A*STAR alone has established 14 new 
institutes with seven dedicated to the 
biomedical sciences (six of the seven 
are housed in the Biopolis complex, 
the brainchild of Sydney Brenner and 
Philip Yeo, which opened in 2003 and 
cost more than US $400 million). Stem 
cell research and regenerative medi-
cine have a valued position in this siz-
able R&D initiative.
Why Stem Cell Research?
There is no doubt that the choice of 
stem cells as a key R&D area for Singa-
pore was heavily influenced by the sig-
nificant contributions of Ariff Bongso, a 
researcher in the Department of Obstet-
rics & Gynecology and Scientific Direc-
tor of the In-Vitro Fertilization program at 
the National University Hospital of Sin-
gapore. It was Bongso’s group that first 
derived human embryonic stem cells 
(hESCs) from 5-day-old human blasto-
cysts (obtained with informed consent 
from local IVF programs; Bongso et al., 
1994). His work paved the way for Jamie 
Thomson at the University of Wiscon-
sin (Thomson et al., 1998) to produce 
long-lived hESC cultures by improv-
ing the disaggregation conditions and 
using permanent feeder cell layers. It 
was this ability to derive hESCs and to 
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As part of the phase 2 expansion of the Biopolis biomedical sciences complex in Singapore, two new 
buildings opened on the Biopolis campus in October 2006. Neuros (left) and Immunos (right) currently 
host the A*STAR Institute of Medical Biology, which houses the Singapore Stem Cell Consortium, and 
the A*STAR Singapore Immunology Network. The buildings also provide space for start-up biomedical 
companies, and there are tentative plans to site a major neurobiology initiative here. Photo courtesy of 
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maintain them in culture that triggered 
the tremendous excitement in stem cell 
research and its application to regenera-
tive medicine in the late 1990s.
Following Bongso’s discovery, Sin-
gapore established its first stem cell 
start-up company, ES Cell International 
Pte Ltd (ESI), in June 2000 (http://www. 
escellinternational.com). Singapore now 
has more than 40 research groups located 
at universities, hospitals, and research 
institutes that are pursuing various facets of 
stem cell research. Institute-based groups 
have access to core funding, whereas oth-
ers can compete with the wider research 
community for government project and 
program grants. Since 2000, more than 
US $20 million has been granted for stem 
cell research in Singapore. More recently, 
scientists have been able to seek spe-
cific support from the A*STAR Singapore 
Stem Cell Consortium (SSCC; http://www.
sscc.a-star.edu.sg). Housed in the new 
A*STAR Institute of Medical Biology—as 
part of phase 2 of the Biopolis expansion 
(Figure 1)—the SSCC will be administer-
ing ~US $75 million of government money 
for intramural and extramural stem cell 
research over 5 years. This compares 
favorably with the US $3 billion made 
available by Proposition 71 (in the form of 
repayable bonds) over a 10 year period for 
stem cell research in California.
Stem Cell Research and Economic 
Priorities
Ten of the world’s leading pharma, bio-
tech, and contract manufacturing com-
panies have manufacturing facilities for 
pharmaceutical production in Singa-
pore. In addition, Lonza, Genentech, and 
Novartis have set up commercial-scale 
biologics manufacturing facilities to 
produce protein therapeutics. Will stem 
cell research be able to bestow similar 
tangible benefits on the Singaporean 
economy?
A big goal is for Singapore to develop 
and manufacture cell-based therapies 
for treating a range of degenerative dis-
eases including heart failure, eye dis-
ease, cartilage repair, and diabetes. In 
so doing, Singapore hopes to serve as 
a medical hub for foreign patients seek-
ing stem cell-based treatments. This 
challenging objective will be facilitated 
by the new A*STAR Singapore Institute 
of Clinical Sciences (SICS) opened in 520 Cell 132, February 22, 2008 ©2008 Elsev2007 and directed by Stanford cardiolo-
gist Judith Swain. SICS will be respon-
sible for training clinician-scientists 
and will act as a critical bridge linking 
basic research undertaken by A*STAR 
research institutes and universities with 
clinical research programs in Singa-
pore’s hospitals and disease centers. 
Another bridge between academia and 
clinical medicine is provided by the Duke 
University-National University of Singa-
pore Graduate Medical School campus 
established in 2005. Here, US faculty 
from Duke University in North Carolina 
train foreign and local medical gradu-
ates, as well as importing and imple-
menting Duke’s acclaimed expertise in 
translational medical research.
Singapore plans to become a provider 
of new human embryonic and adult stem 
cell lines and of reagents for drug discov-
ery and drug testing, an objective facili-
tated by the new A*STAR Experimental 
Therapeutics Centre also opened last year 
and led by British cancer researcher David 
Lane. In this center, cutting-edge scientific 
drug discovery teams will cohabit with 
business development operations.
The wide variety of new research ini-
tiatives create much-needed additional 
PhD and postdoctoral opportunities for 
Singaporeans. Training of the next several 
generations of home-grown scientists is 
central to the Government’s vision of eco-
nomic development and will involve public 
sector research facilities as well as pri-
vately funded research endeavors like the 
Temasek Life Sciences Institute. By 2015, 
A*STAR alone aims to produce a further 
1000 PhD level Singaporean scientists 
trained both locally and in selected insti-
tutions abroad. In addition, Singapore has 
proved remarkably adept at attracting top 
scientists from around the world—the latest 
recruit is embryologist Davor Solter, previ-
ously Director of the Max Planck Institute 
of Immunobiology in Freiburg, Germany, 
who joined the Institute of Medical Biology 
last month as a principal investigator. Cur-
rently, there are over 5000 PhDs working in 
R&D in Singapore, over half of whom hold 
foreign citizenship.
Stem Cells: From Bench to Bedside
Given the history, it is not surprising 
that there is a focus in Singapore on 
basic hESC research recently exempli-
fied by work on pluripotency genes and ier Inc.the hESC epigenetic landscape (Zhang 
et al., 2006; Zhao et al., 2007). In addi-
tion, ESI has generated six new hESC 
lines (grown on human feeder layers) 
to Good Manufacturing Practice (GMP) 
standards (Crook et al., 2007), furthering 
Singapore’s goal of being an important 
provider of hESC lines. (ESI already pro-
vides 6 of the 21 NIH-registered hESC 
lines that became eligible for US federal 
research funding by presidential decree 
on August 9, 2001.) The new hESC lines 
hopefully will simplify the entry of hESC-
derived cell products to the clinic. Most 
hESC lines are derived using mouse cell 
feeder layers, which is problematic for 
clinical application because exposure of 
hESCs to live animal cells greatly com-
plicates the design and operation of any 
clinical trial.
In contrast to, for example, the United 
States and Germany, Singapore does 
not have unduly onerous political or leg-
islative restrictions on hESC research 
and has not enacted any specific legisla-
tion on the generation and use of hESCs. 
Instead, researchers in Singapore adhere 
strictly to guidelines drafted in 2002 by 
the Bioethics Advisory Committee (and 
subsequently endorsed by the Govern-
ment), which were modeled on existing 
UK legislation. Singapore does regulate 
by law the activities of all fertility cen-
ters in Singapore, which could provide 
human eggs or embryos for research. 
Although the upcoming US presidential 
election may result in lifting of the ban 
on federal support for hESC research in 
the United States, other impediments to 
such research remain. For example, the 
1996 Dickey-Wicker Amendment forbids 
U.S. federal support of research involv-
ing the creation or destruction of human 
eggs and embryos.
In a recent remarkable development, 
Japanese researcher Shinya Yamanaka 
and his colleagues (Takahashi et al., 
2007) succeeded in converting adult 
human somatic cells into induced pluri-
potent stem (iPS) cells with very simi-
lar properties to hESCs (see Review 
by R. Jaenisch and R. Young in this 
issue of Cell). This demonstration may 
remove the stigma attached to work-
ing with hESCs in some countries, but 
the challenge of correctly directing the 
differentiation of any stem cell, whether 
an hESC or an iPS cell, is still a daunt-
ing one. Although purity, scale up, and 
efficacy present significant hurdles to 
the clinical development of all stem cell 
products, use of hESCs poses particu-
lar safety risks including the formation 
of teratomas. This and the need to avoid 
immunogenicity issues by using autolo-
gous sources of starting material make 
it more likely that adult stem cell-derived 
products will be the first to achieve mar-
keting approval.
There has been progress in Singapore 
in moving adult human stem cells from 
the bench into the clinic. For example, 
preclinical work with rabbits and pigs 
has led to early clinical trials in which 
patients receive autologous mesenchy-
mal stem cell transplants to effect carti-
lage repair (Lee et al., 2007). Meanwhile, 
at the Singapore Eye Research Institute, 
investigators have performed surgery 
on 48 patients with a variety of ocular 
surface injuries using autologous trans-
plants of cultivated human conjuctival 
stem cell explants and limbal stem cell 
explants (Tan et al., 2004).
Yet despite the investment in stem cell 
research in Singapore and the strong 
pharma presence, many financial chal-
lenges remain before stem cells can be 
translated into viable clinical products. 
For example, the investment by large 
pharmaceutical/biotech companies into 
in-house or externally sponsored cell 
therapy has been noticeably lacking 
in Singapore as it has been elsewhere 
(with the exception of Genzyme-spon-
sored autologous myoblast transplan-tation clinical trials in Europe). Although 
many of these companies regard stem 
cell research as extremely important 
for drug discovery and screening (see 
Essay by L. Rubin in this issue), they 
are concerned about the timelines of 
getting robust cell-based products to 
the market and remain unconvinced by 
the business case for cell therapy. This 
same reticence to invest is shared by 
many venture capitalists making it very 
difficult for private cell therapy compa-
nies to survive (see Analysis by A. Par-
son in this issue).
Future Prospects
With its generous funding and an ultra-
modern centralized and integrated sci-
entific and clinical infrastructure, Sin-
gapore is well placed to tackle the big 
technical challenges of bringing stem 
cells from the laboratory into the clinic. 
Singapore is also well positioned to 
address the regulatory (safety, efficacy) 
and commercial (affordable products) 
challenges that stem cells, in particular 
hESCs, pose for translational medicine. 
The drive to attract foreign talent and to 
nurture home-grown talent continues 
and will not abate for the foreseeable 
future. Indeed, the Singaporean Govern-
ment views its investment in biomedical 
R&D as at least a 20 year project. The 
bottom line is that Singapore’s contin-
ued survival as a rich nation depends on 
each pillar of its economy thriving opti-
mally. Few motivations for success in 
research can be quite as strong as this.Cell 132,ACknowledgmentS
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